A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis

What Was Tested

This randomized controlled trial paper looks at Vasopressin and Desmopressin.

Desmopressin is a useful treatment for primary nocturnal enuresis (PNE), a common childhood condition that can persist into adolescence.

In total, 221 patients aged 5-15 years who were already receiving desmopressin tablets were randomised 1 : 1 to receive desmopressin treatment in the order MELT/tablet (n = 110) or tablet/MELT (n = 111) for 3 weeks each.

Following treatment, patients were questioned regarding treatment preference.

Who Took Part

The abstract describes 221 patients taking part.

By PubMed's age tags, the people studied were children and teenagers, both men and women.

How the Study Was Run

The design is described as randomized, open-label and crossover.

The patients were allocated by chance, so the Vasopressin group and the comparison group should start out alike.

Everyone knew when Vasopressin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Each person switched between Vasopressin and the comparison at some point, usually with a gap in between.

The methods mention a period of 3 weeks.

What Was Measured

The subject headings attached to it are Antidiuretic Agents, Deamino Arginine Vasopressin and Nocturnal Enuresis.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Vasopressin and Desmopressin in 221 patients over 3 weeks.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2007 (International journal of clinical practice), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.